Please login to the form below

Not currently logged in
Email:
Password:

GLP1 agonists

This page shows the latest GLP1 agonists news and features for those working in and with pharma, biotech and healthcare.

EMA: no new safety concerns with GLP-1 diabetes drugs

EMA: no new safety concerns with GLP-1 diabetes drugs

The GLP-1 based therapy class includes both glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors.

Latest news

  • US charity calls for release of diabetes drug data US charity calls for release of diabetes drug data

    The concerned products comprise GLP-1 agonists, such as Byetta/Bydureon (exenatide) from Amylin/ Bristol Myers Squibb (BMS) and Victoza (liraglutide) from Novo Nordisk, as well as the DPP-4 inhibitors, ... data that reinforced "growing safety concerns"

  • Drug delivery

    Other deals of note were Boehringer Ingelheim's (BI) agreement with Zealand Pharma for rights to its ZP2929 - GLP1 receptor agonists against type 2 diabetes and obesity, further building the ... agonists (T2D and obesity). Development, Commercialisation

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics